Brief: United Laboratories International Says US FDA Approved UBT251 Injection For Phase II Clinical Trial
03/03/2025 16:22
March 3 (Reuters) - United Laboratories International Holdings Ltd 3933.HK: UBT251 INJECTION APPROVED FOR PHASE II CLINICAL TRIAL BY U.S. FOOD AND DRUG ADMINISTRATION Further company coverage: 3933.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million